Browse PTGER1

Summary
SymbolPTGER1
Nameprostaglandin E receptor 1 (subtype EP1), 42kDa
Aliases EP1; prostaglandin E receptor 1 (subtype EP1), 42kD; PGE receptor EP1 subtype; PGE receptor, EP1 subtype; PG ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an important modulator of renal function. Implicated the smooth muscle contractile response to PGE2 in various tissues.

> Gene Ontology
 
Biological Process GO:0002237 response to molecule of bacterial origin
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007189 adenylate cyclase-activating G-protein coupled receptor signaling pathway
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0032496 response to lipopolysaccharide
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0055074 calcium ion homeostasis
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
Molecular Function GO:0004953 icosanoid receptor activity
GO:0004954 prostanoid receptor activity
GO:0004955 prostaglandin receptor activity
GO:0004957 prostaglandin E receptor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04020 Calcium signaling pathway
hsa04080 Neuroactive ligand-receptor interaction
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-391903: Eicosanoid ligand-binding receptors
R-HSA-416476: G alpha (q) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-391908: Prostanoid ligand receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolPTGER1
Nameprostaglandin E receptor 1 (subtype EP1), 42kDa
Aliases EP1; prostaglandin E receptor 1 (subtype EP1), 42kD; PGE receptor EP1 subtype; PGE receptor, EP1 subtype; PG ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PTGER1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PTGER1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23390011Colon CarcinomaInhibit immunity (infiltration)Targeting the EP1 receptor reduces Fas ligand expression and increases the antitumor immune response in an in vivo model of colon cancer. PGE2 signals through four different receptors (EP1-EP4) and targeting individual receptor(s) may avoid these side effects, while retaining significant anticancer benefits. This antitumor effect was associated with reduced Fas ligand expression and attenuated tumor-induced immune suppression. In particular, tumor infiltration by CD4(+) CD25(+) Foxp3(+) regulatory T cells was decreased, whereas the cytotoxic activity of isolated splenocytes against CT26 cells was increased.
Summary
SymbolPTGER1
Nameprostaglandin E receptor 1 (subtype EP1), 42kDa
Aliases EP1; prostaglandin E receptor 1 (subtype EP1), 42kD; PGE receptor EP1 subtype; PGE receptor, EP1 subtype; PG ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PTGER1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPTGER1
Nameprostaglandin E receptor 1 (subtype EP1), 42kDa
Aliases EP1; prostaglandin E receptor 1 (subtype EP1), 42kD; PGE receptor EP1 subtype; PGE receptor, EP1 subtype; PG ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PTGER1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5790.144
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.1150.082
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1980.724
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0840.923
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0430.412
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.4940.285
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0060.979
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PTGER1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPTGER1
Nameprostaglandin E receptor 1 (subtype EP1), 42kDa
Aliases EP1; prostaglandin E receptor 1 (subtype EP1), 42kD; PGE receptor EP1 subtype; PGE receptor, EP1 subtype; PG ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PTGER1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPTGER1
Nameprostaglandin E receptor 1 (subtype EP1), 42kDa
Aliases EP1; prostaglandin E receptor 1 (subtype EP1), 42kD; PGE receptor EP1 subtype; PGE receptor, EP1 subtype; PG ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PTGER1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PTGER1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPTGER1
Nameprostaglandin E receptor 1 (subtype EP1), 42kDa
Aliases EP1; prostaglandin E receptor 1 (subtype EP1), 42kD; PGE receptor EP1 subtype; PGE receptor, EP1 subtype; PG ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PTGER1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPTGER1
Nameprostaglandin E receptor 1 (subtype EP1), 42kDa
Aliases EP1; prostaglandin E receptor 1 (subtype EP1), 42kD; PGE receptor EP1 subtype; PGE receptor, EP1 subtype; PG ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PTGER1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPTGER1
Nameprostaglandin E receptor 1 (subtype EP1), 42kDa
Aliases EP1; prostaglandin E receptor 1 (subtype EP1), 42kD; PGE receptor EP1 subtype; PGE receptor, EP1 subtype; PG ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PTGER1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPTGER1
Nameprostaglandin E receptor 1 (subtype EP1), 42kDa
Aliases EP1; prostaglandin E receptor 1 (subtype EP1), 42kD; PGE receptor EP1 subtype; PGE receptor, EP1 subtype; PG ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PTGER1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PTGER1.
ID Name Drug Type Targets #Targets
DB00297BupivacaineSmall MoleculePTGER1, SCN10A2
DB00429Carboprost TromethamineSmall MoleculePTGER11
DB00770AlprostadilSmall MoleculePTGDR2, PTGER1, PTGER23
DB00905BimatoprostSmall MoleculeAKR1C3, PTGER1, PTGER3, PTGFR4
DB00917DinoprostoneSmall MoleculePTGDR2, PTGER1, PTGER2, PTGER3, PTGER45
DB01088IloprostSmall MoleculePDE4A, PDE4B, PDE4C, PDE4D, PLAT, PTGDR2, PTGER1, PTGIR8
DB09211LimaprostSmall MoleculePTGER1, PTGER2, PTGER3, PTGER44